Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia.
Recombinant activated factor VII (rFVIIa) is a major alternative for management of hemophiliac patients with inhibitors. Additionally, it has been used off-label for the treatment of massive life-threatening hemorrhage associated with various bleeding situations. Herein, we describe a 16-month-old boy with acute megakaryoblastic leukemia and severe intractable gastrointestinal bleeding controlled by rFVIIa. rFVIIa should be considered as a novel treatment alternative in severe bleeding conditions including leukemias that may have hemostatic defects and platelet dysfunction.
Kurekci
A Emin
AE
Department of Pediatric Hematology, Gulhane Military Medical Academy, Ankara, Turkey. ekurekci@gata.edu.tr
Atay
A Avni
AA
Okutan
Vedat
V
Yavuz
S Tolga
ST
Ozcan
Okan
O
D005167:Factor VII / Q000008:administration & dosage*; D015942:Factor VIIa; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D007947:Leukemia, Megakaryoblastic, Acute / Q000150:complications / Q000188:drug therapy; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage*
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa